MAVENIR
10.1.2022 09:02:11 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that BAI Communications (BAI), a global communications infrastructure provider, will be launching a Smart City project for Sunderland City Council in the north of England (UK), powered by Mavenir’s MAVedge solution.
BAI Communications will build a new 5G centric network to accelerate adoption of transformative digital services for sectors including manufacturing and logistics, education and social care. The initial scope is for the deployment of a city-centre 5G private network which has the potential to evolve and become a neutral host network.
Neutral host models provide coverage and connectivity for smart city initiatives. They enable local councils and authorities to provide smart services and run numerous smart community applications in a more viable and cost-effective manner.
MAVedge comprises Mavenir’s leading edge Open vRAN and 5G Packet Core solutions to drive the next generation digital transformation of this Smart City project, and to provide advanced 5G mobile connectivity to the local Sunderland community. MAVedge enables secure private networks to be distributed at the edge and powers a digital marketplace of applications and devices to create an efficient environment for diverse use cases for the enterprise and industry.
The 5G Open vRAN and 5G Packet Core solutions are designed with cloud-native virtualisation techniques providing a fully scalable and virtualised network architecture with open standard interfaces. The Open RAN platform provides BAI Communications the option of deploying radio units from different vendors. The solution uses software running on commercial off the shelf (COTS) hardware that provides cost effectiveness, flexibility and agility, whilst delivering one architecture as a baseline for many different use cases.
The new network will help accelerate transformation within various sectors in Sunderland including:
- Smart Homes: addressing health and social care requirements supporting vulnerable individuals living in their own homes, providing access to assistive technologies such as sensors and other IoT enabled devices.
- Digital Skills and Education: providing enhanced online and remote connectivity and distance learning across Primary Schools and Secondary Schools within the local authority.
- Manufacturing and Industry 4.0: improving supply chain agility for the automotive industry, including applications such as self-driving vehicles and autonomous heavy goods vehicles.
“Open RAN is a cost-effective solution which is based on open interfaces and will give us the ability to deploy in a very agile and flexible way,” said Brendan O’Reilly, Group Chief Technology Officer at BAI Communications. “We are delighted to work with Mavenir, a technology innovator company in cloud-native virtualised solutions and a leading player in the Open RAN initiative and 5G Core. Technology we believe will help accelerate Sunderland’s ambitions to become one of the UK’s most advanced smart cities, connecting people, communities and businesses.”
“BAI Communications represents an ideal partner for this prestigious smart city project in Sunderland. Together, we will be able to build new RAN and Packet Core domains that will deliver the flexibility needed for a diverse set of cross-sector use cases. Virtualised solutions from Mavenir are the perfect choice of technology with Open vRAN and Cloud-Native Packet Core. The objective is to automate operations and flex the scalability in neutral hosting architecture, whilst delivering benefits not only to enterprises and business users, but also for the wider community,” said Stefano Cantarelli, Chief Marketing Officer at Mavenir.
“We are creating a new digital fabric for Sunderland’s City, upon which the City’s digital and business entrepreneurs can build – a portfolio of new digital services for the benefits of residents, businesses and visitors,” says Andrew Conway, Director of Solutions and Innovation at BAI Communications UK.
Liz St Louis, Assistant Director of Smart Cities at Sunderland City Council, said, “We have long recognised the importance of technology in connecting people and realising opportunities to position Sunderland as a digital frontrunner. This new partnership between BAI Communications and Mavenir presents a fully scalable network architecture to unlock innovation and shape the future of our leading smart city.
“Together, we are harnessing the power of technology and digital transformation for the benefit of residents, businesses and visitors to Sunderland. The new network will accelerate the emergence of more smart services including community applications, digital upskilling opportunities and efficiency drives for our advanced manufacturing clusters across the city.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About BAI Communications:
BAI Communications is a world leader in shared communications infrastructure, pioneering solutions that empower our customers to advance their services, accelerate their networks and amplify their reach in the most efficient and cost-effective ways possible. Having long been at the forefront of network advancement, BAI is harnessing fibre, spearheading the transition from 4G/LTE, accelerating 5G and preparing for 6G – and beyond. We collaborate closely with our customers in MNOs, government, transit, enterprise, broadcasting and venues to realise their communications vision, focusing not just on the immediate future, but on the possibilities that exist over long-term partnerships. Our global operations span Australia, Canada, Hong Kong, United Kingdom and in the United States through BAI Group company, Mobilitie , and majority-owned Transit Wireless . Together, we’re creating smarter communities for all. https://www.baicommunications.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005089/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom